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ABSTRACT
Bladder and kidney cancer are the 10th and 7th
most common cancers in the United Kingdom
(UK). They present with symptoms that are typ-
ically investigated via the same diagnostic path-
way. However, diagnosing these cancers can be
challenging, especially for kidney cancer, as
many of the symptoms are non-specific and
occur commonly in patients without cancer.
Furthermore, the recognition and evaluation of
these symptomsmay differ because of the lack of
supporting high-quality evidence to inform
management, a problem also reflected in cur-
rently ambiguous guidelines. The majority of
these two cancers are diagnosed following a
referral fromageneral practitioner. In this article,
we summarise current UK and United States (US)
guidelines for investigating common symptoms
of bladder and kidney cancer—visible haema-
turia, non-visible haematuria and urinary tract
infections. Our article aims to support clinicians
in recognising and investigating patients with
symptoms of possible bladder and kidney
cancer in a timely fashion.Wediscuss challenges
during the diagnostic process and possible future
interventions for improvement.
Keywords: Bladder cancer; Early diagnosis;
Kidney cancer; Primary care; Urological cancer
INTRODUCTION
Around 10,000 and 12,500 patients were diag-
nosed with bladder and kidney cancer respec-
tively in the UK in 2015 [1]. While the
incidence of bladder cancer is predicted to
remain stable, kidney cancer is expected to be
among the cancers with the fastest increasing
incidence over the next 20 years [2]. Currently,
these cancers are more common in men than
women, with men being about 3 times and 1.7
times as likely as women to be diagnosed with
bladder and kidney cancer respectively [2, 3].
In the UK, most bladder cancer (almost 70%)
is diagnosed following a referral from a general
practitioner (GP) [3]. The percentage of those
diagnosed via a fast-track GP referral (‘‘two-
week-wait’’ referral in England) has been
increasing year on year from 38% in 2011 to
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43% of all bladder cancer diagnosed in 2015 [3].
This may partly reflect public health interven-
tions such as the ‘‘Be Clear on Cancer’’ cam-
paign, aiming to increase public awareness of
alarm symptoms such as haematuria [4]; fur-
ther, it may be related to progressive changes in
clinical practice due to the implementation of
clinical guidelines, clinical audit initiatives and
the introduction of new referral pathways.
Kidney cancer patients, on the other hand, have
a more varied route to diagnosis. Although
almost 60% are still diagnosed following a GP
referral; about a third (28% and 31% respec-
tively) were diagnosed via the fast-track and
non-fast track route in 2015 [3]. Kidney cancer
is also associated with a slightly higher rate of
emergency presentation than bladder cancer,
with about a fifth (21% and 18% respectively)
diagnosed through an emergency route [3],
which is associated with poorer stage at diag-
nosis and survival [5]. Given that the majority
of these two cancers are diagnosed following
presentation in primary care, timely recogni-
tion, diagnostic testing and referral decisions by
GPs are paramount to improve outcomes [6].
Current evidence indicates that women with
bladder cancer experience a longer time to
diagnosis, more advanced stage at diagnosis and
worse survival, even if adjusted for stage at
diagnosis, than men [7–10]. The effects of dif-
ferent exposures to risk factors and the role of
biological mechanisms, such as sex steroids
triggering cancer development and influencing
treatment effects, have been implicated in
gender disparities in cancer incidence and sur-
vival [11, 12]. However, it is likely that variable
diagnostic testing strategies by clinicians also
contribute to the observed differences in how
quickly these cancers are diagnosed.
We provide an overview of current relevant
UK and US guidelines, highlight their limitations
and suggest a practical approach to the evalua-
tion of patients presenting in primary care with
symptoms of possible bladder or kidney cancer.
We focused on the National Institute for Clinical
Excellence (NICE) guidelines (developed in Eng-
land and also adopted and in use in Wales and
Northern Ireland), Scottish and American
guidelines to present recommendations from
three systematically developed guidelines to
guide the discussion, highlight discrepancies and
areas for future research. As the symptoms of and
initial investigations for these two cancers are
similar, we consider them together. Hereafter
urological cancers denote bladder and kidney
cancers only (and not prostate cancer), unless
otherwise stated. Although sections of this article
focus on the diagnostic pathway in the UK, the
principles underlying the evaluation strategies
discussed here will be of relevance to primary
care clinicians working in countries around the
world.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
SYMPTOM SIGNATURE
Clinicians should consider both the symptom
signature of a cancer and the predictive values
of possible cancer symptoms during the diag-
nostic evaluation for possible cancer.
Symptom signature of a cancer refers to the
nature and relative frequency of presenting
symptom(s) in patients with that cancer. Blad-
der cancer has a narrow symptom signature
dominated by a symptom with high predictive
value [13]; that is, most patients with bladder
cancer present with haematuria, a symptom
with relatively high positive predictive value
(PPV). In contrast, kidney cancer has a broad
symptom signature with symptoms of varying
predictive value, some of which may have rel-
atively high PPVs (e.g. haematuria), while oth-
ers have low PPVs (e.g. abdominal pain). Taking
visible haematuria as an example, it was repor-
ted to be present in over half (53%) of bladder
cancer patients [14] and less than one-fifth
(18%) of kidney cancer patients [15].
Diagnostic difficulty is therefore a function of
both the symptom signature and PPV of symp-
tom(s). Fast-track referral pathways, based on
alarm symptoms with high PPVs, will improve
early diagnosis of cancers such as bladder cancer,
but are less helpful for kidney cancer.
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EVALUATING SYMPTOMS
OF POSSIBLE UROLOGICAL
CANCER
Visible Haematuria
A systematic review published by Schmidt-
Hansen et al. found that visible haematuria has
the highest PPV (5.1%) of any symptom for
urological cancer in the primary care setting. It
is more predictive of bladder than kidney cancer
[16], and the predictive value is dependent on
age (higher in older/lower in younger patients)
and sex (higher in men than women). Visible
haematuria is regarded as an alarm symptom for
urological cancer [17], with the likelihood that
haematuria is due to urological cancer increas-
ing with age [16]. The varying age cut-offs that
have been used in the three guidelines described
below reflect the acceptable cost-effectiveness
thresholds in the various health systems of
potential subsequent investigations required to
action upon the patients who fulfil these crite-
ria. Clinicians should have a low threshold for
referring patients urgently with visible haema-
turia for further investigations, according to
their national/local age thresholds for referrals.
Both the NICE and Scottish guidelines rec-
ommend that GPs refer patients presenting with
visible haematuria urgently via the fast-track
pathway [18, 19]. While the Scottish guidelines
advise referring all patients with painless visible
haematuria (no age threshold mentioned),
NICE guidelines recommend a referral only in
those aged 45 and over with these symptoms.
The American Urological Association (AUA)
recommends that all patients aged 35 and above
with visible (and non-visible) haematuria be
investigated [20] (Table 1). Following a referral,
the typical secondary care investigative path-
way usually consists of at least cystoscopy and
upper urinary tract imaging [20].
Non-Visible Haematuria
While GPs are reasonably good at considering
visible haematuria as an alarm symptom for
possible urological cancer, variations in clinical
practice exist regarding the investigation of
non-visible haematuria. Varying PPVs for can-
cer between 2.5% and almost 20% have been
reported for non-visible haematuria depending
on the study population [21], with lower values
reported in primary care (about 1.6% [16])—
likely explaining the differences in approaches
to management of this symptom.
The cancer detection rates in patients with
non-visible haematuria differ by whether they
are symptomatic or not, with symptomatic
patients associated with a higher cancer detec-
tion rate (e.g. 9.1% vs 1.5% in a referred popu-
lation with haematuria in a single institution in
Denmark [22]). The approach to managing non-
visible haematuria therefore differs by whether
these patients also have other symptoms.
The AUA guidelines recommend that all
patients aged 35 and over with non-visible
haematuria confirmed on urine microscopy
(whether symptomatic or not) should undergo
cystoscopy and renal tract imaging [20], while
the NICE guidelines recommend an urgent
referral only in patients aged 60 and over with
an additional symptom (dysuria) or raised white
cell count on a blood test [18]. A large US study
consisting of over 9000 patients aged 65 years
and above with non-visible haematuria found
that 65% had no further evaluation or referral
up to 6 months after presentation [23].
Although a proportion of these non-evaluated
cases may be justifiable, it is likely that some
may represent potential missed diagnostic
opportunities especially in patients of this age
group. An additional challenge is the lack of
consensus of guidelines on the management of
asymptomatic non-visible haematuria, which
report varying age thresholds for further diag-
nostic evaluation [24], likely reflecting the lack
of high-quality evidence supporting the man-
agement of this patient group.
In those with asymptomatic non-visible
haematuria, a clinician should also consider the
possibility of renal pathology, and provide fol-
low-up advice to patients, as to how and when
to reappraise their symptoms, and re-present
should primary care tests yield negative results.
The AUA suggests that transient or benign
causes of non-visible haematuria such as infec-
tion, menstruation and recent urological pro-
cedures be assessed and treated [20].
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Symptomatic patients should be advised to
return after antibiotic treatment for their uri-
nary tract infections (UTIs) or benign condition
to ensure the resolution of non-visible haema-
turia. Further investigations should be per-
formed in people with persistent symptomatic
non-visible haematuria. Figure 1 shows a prac-
tical way of managing non-visible haematuria
for a GP working in England, taking into
account NICE guidelines and published expert
opinion [18, 21]. Future research should also
aim to identify the groups of patients who will
benefit from active monitoring of their
symptoms and signs, and the cost-effectiveness
of such approaches.
Non-Haematuria Symptoms and Symptom
Combinations
Besides visible haematuria, the PPVs of other
clinical features in primary care including non-
visible haematuria, UTI, abdominal pain, back
pain, dysuria, fatigue, constipation, nausea, loss
of appetite and deep vein thrombosis are all well
below the 3% NICE threshold for referrals for
Table 1 Recommendations for different clinical features from various guidelines
Clinical feature Age
threshold
Recommendation Guideline
Visible haematuria
Visible haematuria without UTI or after treating UTI Aged 45? Urgent referral NICE
Painless visible haematuria None Urgent referral Scottish Cancer Referral
Guidelines [19]
Visible haematuria Aged 35? Cystoscopy
imaging
AUA
Non-visible haematuria
NVH with either dysuria or raised WCC Aged 60? Urgent referral NICE
Asymptomatic persistent NVH None Non-urgent Scottish Cancer Referral
Guidelines
Asymptomatic NVH (conﬁrmed by urine microscopy as
[ 3RBC/HPF)
Aged 35? Cystoscopy
imaging
AUA
Any haematuria with symptoms suggestive of UTI but
sterile MSU
None Urgent referral Scottish Cancer Referral
Guidelines
Urinary tract infection (UTI)
Recurrent or persistent UTIs Aged 60? Non-urgent
referral
NICE
Recurrent UTI associated with any haematuria Aged 40? Non-urgent Scottish Cancer Referral
Guidelines
Abdominal mass
Abdominal mass None Urgent referral Scottish Cancer Referral
Guidelines
AUA American Urological Association [20], MSU mid-stream urine, NICE National Institute for Clinical Excellence (in
use in England, Wales and Northern Ireland) [18], NVH non-visible haematuria, RBC/HPF red blood cell per high power
ﬁeld, UTI urinary tract infection, WCC white cell count
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further investigation [16]. Although these indi-
vidual symptoms have low PPVs for cancer,
combinations of ‘‘risks’’, including other symp-
toms, investigations and age have been used to
identify patients at relatively high risk of having
cancer [14, 15]. For example, the 2015 NICE
guideline recommends that patients aged 60
and over with unexplained non-visible haema-
turia and dysuria should be referred on the fast-
track route ([3% PPV). Similarly, Scottish
guidelines recommend an urgent referral in
those with visible haematuria and UTI symp-
toms but sterile urine culture [19]. In the
absence of haematuria, NICE also suggested that
patients with recurrent or persistent UTIs be
considered for a non-urgent referral to a urolo-
gist for further investigations [18], as evidence
indicates that UTIs may be associated with
increased bladder cancer risk [25, 26].
Challenges and Future Directions
Although the evidence regarding PPVs and
symptom signature for urological cancers is
reasonably well established, we describe below
three areas where practical applications of this
Non-visible haematuria
Lower urinary tract symptoms present
MSU 
posive
Treat for 
UTI
Re-check 
dipsck 
aer 
treatment
Consider 
roune 
referral if 
sll 
posive
MSU 
negave 
Aged ≥60
Urgent 
referral
Aged <60
Consider 
roune 
referral
Asymptomac
Exclude transient causes
Re-check dipsck aer treatment of 
transient cause
Persistent NVH on 2 of 3 dipscks (at 
least 1+ blood)
Check BP, urine ACR, eGFR
Aged ≥40
Consider 
urology 
referral
Aged <40
If abnormal 
BP, urine 
ACR, eGFR - 
refer 
ultrasound 
KUB and 
consider 
nephrology 
referral
If normal, 
monitor in 
primary care 
(at least 
annually)
Consider 
nephrology 
referral if 
worsening 
renal funcon 
or proteinuria
Fig. 1 An adapted approach to managing non-visible
haematuria based on NICE [18] (in green) and evidence-
based expert opinion [21] (in orange). ACR albumin-to-
creatinine ratio, BP blood pressure, eGFR estimated
glomerular ﬁltration rate, KUB kidneys ureters bladder,
NVH non-visible haematuria, MSU mid-stream urine,
UTI urinary tract infection
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knowledge can be used to improve early detec-
tion of cancer.
Risk Prediction Tools
The low diagnostic yield of single symptoms
(except visible haematuria) and relatively broad
symptom signature of kidney cancer call for the
development of risk stratification strategies to
identify patients at higher risk of these cancers.
Electronic risk prediction tools, embedded in
medical records, could be developed to incor-
porate socio-demographic and clinical features
[27], assisting clinicians in decision-making.
Existing evidence suggests that risk assessment
tools can be helpful for GPs to consider their
referral thresholds and act as a diagnostic aid by
prompting them to investigate and actively
manage medium- to high-risk patients [28].
Electronic Trigger Tools
Patients, particularly women, are more likely to
be diagnosed with benign conditions such as
UTIs in the year before being diagnosed with
urological cancers [29, 30]. The recurrence and
persistence of symptoms may be an indication
of a possible underlying malignancy. Electronic
trigger tools embedded in existing clinical
information systems can be promising when
used to identify the patients with recurrent or
persistent UTIs who might be at risk of a missed
diagnostic opportunity for cancer [31, 32].
Biomarkers, Point-of-Care and Screening
Tests for Symptomatic and Asymptomatic
Populations
At present, there are no reliable screening tests
for bladder and kidney cancer. Urinary
biomarkers such as NMP22 have been tested
and used to diagnose bladder cancer in symp-
tomatic patients [33], but their use in screening
or in the primary care setting is unknown.
Similarly, ultrasound is being examined in large
multicentre trials to see if they can be a cost-
effective screening method for kidney cancer.
CONCLUSIONS
We summarise existing evidence and guidelines
relating to the management of three common
presenting features of possible bladder and
kidney cancer—visible haematuria, non-visible
haematuria and urinary tract infections. We
recommend that clinicians have a low thresh-
old for investigating visible haematuria, which
has the highest PPV for urological cancer
among all symptoms. We also provide a
flowchart detailing a stepwise approach to
managing non-visible haematuria, which can
be a challenge to manage because of their low
PPV for cancer and paucity of high-quality evi-
dence-based guidelines. Patients with persistent
or recurrent urinary tract infections should also
be considered for non-urgent investigations by
a specialist. Future directions for research
should look into the development, implemen-
tation and evaluation of clinical aids, including
risk assessment tools, electronic triggers for
prompting/reminding clinicians of necessary
follow-up actions and the use of point-of-care
tests and biomarkers in the primary care setting.
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